Risk of second primary cancer among esophageal cancer patients: A pooled analysis of 13 cancer registries
Por:
Chuang, S, Hashibe, M, Scelo, G, Brewster, D, Pukkala, E, Friis, S, Tracey, E, Weiderpass, E, Hemminki, K, Tamaro, S, Chia, K, Pompe-Kim, V, Kliewer, E, Tonita, J, Martos, C, Jonasson, J, Dresler, C, Boffetta, P and Brennan, P
Publicada:
1 jun 2008
Resumen:
Background: The objective of this study is to assess the risk of second primary cancers following a first primary esophageal cancer as well as the risk of esophageal cancer as a second primary, following first primary cancers of other sites.
Methods: The present investigation is a multicenter study of, 13 population-based cancer registries in Europe, Australia, Canada, and Singapore. To assess excess occurrence of second cancers after esophageal cancers, we calculated standardized incidence ratios (SIR) by dividing the observed numbers of second cancers by the expected number of cancers calculated from the accumulated person-years and the age-, sex-, calendar period-, and registry-specific first primary cancer incidence rates.
Results: During the study period, 959 cases of second primary cancers occurred after an initial esophageal cancer, resulting in a SIR of 1.15 (95% confidence interval, 1.08-1.22). Second primary stomach cancers were associated with first primary esophageal adenocarcinomas (SIR, 2.13; 95% confidence interval, 1.263.37) and second primary cancers of the oral cavity and pharynx (6.68; 5.33-8.26), stomach (1.53; 1.14-2.01), larynx (3.24; 1.88-5.18), lung (1.55; 1.28-1.87), kidney (1.88; 1.182.85), and thyroid (2.92; 1.18-6.02) were associated with first primary squamous cell carcinomas of the esophagus. An excess of esophageal cancer as a second primary were observed following first primary cancers of the aerodigestive tract, female breast, cervix, testis, bladder, Hodgkin's lymphoma, and non-Hodgkin lymphoma.
Conclusion: We observed associations of esophageal cancer with second primary head and neck cancers and lung cancer regardless of years of follow-up, which may suggest that common risk factors play a role in multiple tumor development.
Filiaciones:
IARC, F-69008 Lyon, France.
Univ Calif Los Angeles, Sch Publ Hlth, Dept Epidemiol, Los Angeles, CA 90024 USA.
NHS Natl Services, Informat Services, Scottish Canc Registry, Edinburgh, Midlothian, Scotland.
Inst Stat & Epidemiol Canc Res, Finnish Canc Registry, Helsinki, Finland.
Danish Canc Soc, Inst Canc Epidemiol, Copenhagen, Denmark.
New S Wales Canc Registry, Eveleigh, NSW, Australia.
Canc Registry Norway, Oslo, Norway.
Karolinska Inst, Dept Med Epidemiol & Biostat, Stockholm, Sweden.
Samfunde Folkhalsan, Dept Genet Epidemiol, Helsinki, Finland.
German Canc Res Ctr, Div Mol Genet Epidemiol, Heidelberg, Germany.
Karolinska Inst, Ctr Family & Community Med, Huddinge, Sweden.
British Columbia Canc Agcy, Vancouver, BC V5Z 4E6, Canada.
Ctr Mol Epidemiol, Singapore, Singapore.
Singapore Canc Registry, Singapore, Singapore.
Canc Registry Slovenia, Inst Oncol, Ljubljana, Slovenia.
Univ Manitoba, CancerCare Manitoba, Epidemiol & Canc Registry, Winnipeg, MB, Canada.
Univ Manitoba, Community Hlth Sci, Winnipeg, MB, Canada.
Saskatchewan Canc Agcy, Regina, SK, Canada.
Canc Registry Zaragoza, Hlth Dept Aragon Govt, Zaragoza, Spain.
Univ Iceland, Iceland Canc Soc, Iceland Canc Registry, Reykjavik, Iceland.
Univ Iceland, Fac Med, Reykjavik, Iceland.
|